List view / Grid view

Eculizumab (Soliris)

 

article

Boom times for pharma M&A

18 February 2021 | By

Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…